Remtolumab  (Synonyms: ABT-122)

Remtolumab is a bispecific variable domain immunoglobulin molecule with human affinities for TNFα and IL-17 in the low pM range of K_d. Remtolumab can be used in research related to rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis^[1][2].

[VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer

Human

Remtolumab (ABT-122) is the lead dual variable domain immunoglobul (DVD-Ig™) candidate selected based on its superior affinity and potency targeting human TNF and human IL-17 relative to other top candidates^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Remtolumab functionally neutralizes the activities of human TNF and IL-17, and inhibits the lethal effect induced by recombinant human TNF-Dgal and the KC production induced by recombinant human IL-17 in mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7124  [NCBI] & 3605  [NCBI]

P01375 & Q16552

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

198.31 kDa

1791410-27-9

Liquid

Colorless to light yellow

[Remtolumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer

• 
  Immobilized Human TNF-alpha Protein can bind Remtolumab. The EC₅₀ for this effect is 2.03 ng/mL.
• 
  Immobilized Human IL-17A Protein can bind Remtolumab. The EC₅₀ for this effect is 5.32 ng/mL.

• [1]. C.-M. Hsieh, et al. FRI0303 Discovery and Characterization of Abt-122, an Anti-TNF/IL-17 Dvd-Ig™ Molecule as A Potential Therapeutic Candidate for Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 2014;72(2).

  [2]. Havnaer A, et al. Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments. Cutis. 2019;104(2S):17-20.  [Content Brief]